StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Stock analysts at StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Get Rating) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.

ONCT has been the topic of a number of other reports. HC Wainwright cut Oncternal Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, April 4th. Brookline Capital Acquisition restated a “hold” rating on shares of Oncternal Therapeutics in a research report on Tuesday, April 4th. Cantor Fitzgerald lowered Oncternal Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Thursday, April 6th. Brookline Capital Management lowered Oncternal Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 3rd. Finally, Maxim Group lowered Oncternal Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 4th. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $5.77.

Oncternal Therapeutics Stock Performance

Shares of ONCT opened at $0.29 on Monday. The stock’s 50-day simple moving average is $0.51 and its 200 day simple moving average is $0.84. The stock has a market capitalization of $16.79 million, a price-to-earnings ratio of -0.34 and a beta of 1.55. Oncternal Therapeutics has a 52-week low of $0.26 and a 52-week high of $1.87.

Insider Transactions at Oncternal Therapeutics

In other news, CEO James B. Breitmeyer acquired 100,000 shares of Oncternal Therapeutics stock in a transaction that occurred on Thursday, April 13th. The stock was bought at an average price of $0.29 per share, for a total transaction of $29,000.00. Following the completion of the transaction, the chief executive officer now owns 146,544 shares in the company, valued at $42,497.76. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders acquired 160,000 shares of company stock worth $46,650 over the last quarter. 6.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Oncternal Therapeutics

Hedge funds have recently made changes to their positions in the business. Waypoint Capital Advisors LLC purchased a new stake in shares of Oncternal Therapeutics in the fourth quarter worth about $38,000. Two Sigma Investments LP raised its holdings in shares of Oncternal Therapeutics by 136.0% in the third quarter. Two Sigma Investments LP now owns 356,244 shares of the company’s stock worth $318,000 after buying an additional 205,312 shares during the period. Vanguard Group Inc. raised its holdings in shares of Oncternal Therapeutics by 34.1% in the third quarter. Vanguard Group Inc. now owns 2,863,217 shares of the company’s stock worth $2,553,000 after buying an additional 728,200 shares during the period. Renaissance Technologies LLC grew its stake in Oncternal Therapeutics by 52.2% in the third quarter. Renaissance Technologies LLC now owns 979,800 shares of the company’s stock worth $874,000 after purchasing an additional 336,066 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Oncternal Therapeutics by 13.0% in the second quarter. Goldman Sachs Group Inc. now owns 189,634 shares of the company’s stock worth $211,000 after purchasing an additional 21,785 shares in the last quarter. Institutional investors own 16.66% of the company’s stock.

Oncternal Therapeutics Company Profile

(Get Rating)

Oncternal Therapeutics, Inc engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534. The company was founded by David F. Hale and James B. Breitmeyer in September 1997 and is headquartered in San Diego, CA.